Present status and future directions of intracanal medicaments

被引:35
|
作者
Ordinola-Zapata, Ronald [1 ]
Noblett, W. Craig [1 ]
Perez-Ron, Alejandro
Ye, Zhou [2 ,3 ]
Vera, Jorge [4 ]
机构
[1] Univ Minnesota, Sch Dent, Div Endodont, 8-166 Moos Hlth Sci Tower,515 Delaware ST SE, Minneapolis, MN 55455 USA
[2] Univ Hong Kong, Appl Oral Sci & Community Dent Care, Fac Dent, Hong Kong, Peoples R China
[3] Univ Minnesota, Sch Dent, Minnesota Dent Res Ctr Biomat & Biomech MDRCBB, Minneapolis, MN 55455 USA
[4] Univ Missouri, Sch Dent, Endodont Dept, Kansas City, MO USA
关键词
antimicrobial peptides; apical periodontitis; biofilms; calcium hydroxide; ROOT-CANAL TREATMENT; 2-VISIT ENDODONTIC TREATMENT; FACTORS AFFECTING OUTCOMES; CALCIUM HYDROXIDE; APICAL PERIODONTITIS; ENTEROCOCCUS-FAECALIS; SILVER NANOPARTICLES; CHLORHEXIDINE DIGLUCONATE; ONE-VISIT; ROTARY INSTRUMENTATION;
D O I
10.1111/iej.13731
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Two fundamental goals of endodontic treatment are to prevent or treat apical periodontitis. From a predictive perspective, several variables can affect the outcome of root canal treatment. Some of these variables depend on intraoperative factors, which include irrigation technique, size of the apical preparation, use of intracanal medicaments or the number of appointments necessary to complete the treatment. However, the outcome may also be affected by host and microbial factors. The intensity of periradicular bone loss or tissue damage, the presence of preoperative pain and associated conditions such as mechanical allodynia and central sensitization, the anatomical complexity of the apical portion of the canal, and the virulence and longevity of the bacterial infection can all have a profound influence on the outcome. Furthermore, numerous medical conditions have been reported to decrease the capability of the immune system to heal the periapical tissues. It is the clinician's responsibility to analyse these variables and incorporate them into the disinfection strategy to maximize the chances of healing. This narrative review will focus on the present status of intracanal medicaments, the clinical indications for their use and future directions for research.
引用
收藏
页码:613 / 636
页数:24
相关论文
共 50 条
  • [41] PATHOGENESIS OF IDIOPATHIC MYELOFIBROSIS - PRESENT STATUS AND FUTURE-DIRECTIONS
    REILLY, JT
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) : 1 - 8
  • [42] Cardiac Resynchronization Therapy: History, Present Status, and Future Directions
    Jaffe, Leeor M.
    Morin, Daniel P.
    OCHSNER JOURNAL, 2014, 14 (04): : 596 - 607
  • [43] Acute interventions for ischemic stroke: Present status and future directions
    Qureshi, AI
    Ringer, AJ
    Suri, MFK
    Guterman, LR
    Hopkins, LN
    JOURNAL OF ENDOVASCULAR THERAPY, 2000, 7 (05) : 423 - 428
  • [44] PRESENT STATUS AND FUTURE-DIRECTIONS OF PLUTONIUM PROCESS CHEMISTRY
    CHRISTENSEN, EL
    GREY, LW
    NAVRATIL, JD
    SCHULZ, WW
    ACS SYMPOSIUM SERIES, 1983, 216 : 349 - 368
  • [45] THE BIOLOGY OF IGUANINE LIZARDS - PRESENT STATUS AND FUTURE-DIRECTIONS
    TROYER, K
    HERPETOLOGICA, 1983, 39 (03) : 317 - 328
  • [46] TREE DOMESTICATION FOR AGROFORESTRY - PRESENT STATUS AND FUTURE-DIRECTIONS
    KASS, DCL
    AGROFORESTRY SYSTEMS, 1993, 23 (2-3) : 195 - 205
  • [47] Present status and future directions: The restoration of root filled teeth
    Mannocci, Francesco
    Bitter, Kerstin
    Sauro, Salvatore
    Ferrari, Paolo
    Austin, Rupert
    Bhuva, Bhavin
    INTERNATIONAL ENDODONTIC JOURNAL, 2022, 55 : 1059 - 1084
  • [48] Deep margin elevation-Present status and future directions
    Eggmann, Florin
    Ayub, Jose M.
    Conejo, Julian
    Blatz, Markus B.
    JOURNAL OF ESTHETIC AND RESTORATIVE DENTISTRY, 2023, 35 (01) : 26 - 47
  • [49] Molecular epidemiology of hematological neoplasms - Present status and future directions
    Shpilberg, O
    Dorman, JS
    Shahar, A
    Kuller, LH
    LEUKEMIA RESEARCH, 1997, 21 (04) : 265 - 284
  • [50] Gene therapy in wound healing: present status and future directions
    L K Branski
    C T Pereira
    D N Herndon
    M G Jeschke
    Gene Therapy, 2007, 14 : 1 - 10